PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
VARIOUS ANTIANEMIC ANTIDOTE TO FOLIC ACID ANTAGONISTS ANTINEOPLASTIC ADJUNCTS RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL RAPIDLY ABSORBED AND ENTERS THE GENERAL BODY POOL OF REDUCED FOLATES CONVERTED TO 5-METHYLTETRAHYDROFOLIC ACID (5-METHYL-THF)
INJECTION ORAL
VD 16.2 LITER (65 KILOGRAM)
PPB 91 PERCENT
Cl 22.6 LITER / HOUR (65 KILOGRAM)
HT 1.3 HOUR
SOLUBILITY SOLUBLE IN WATER
PDB4LXX (CRYSTAL STRUCTURE WLARD, A SUGAR 3N-FORMYL TRANSFERASE IN THE PRESENCE OF DTDP-FUC3NFO AND 5-N-FORMYL-THF)
PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693)
Primary Target and PDB code of Protein-Drug complex
VARIOUS ANTIANEMIC ANTIDOTE TO FOLIC ACID ANTAGONISTS ANTINEOPLASTIC ADJUNCTS RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL RAPIDLY ABSORBED AND ENTERS THE GENERAL BODY POOL OF REDUCED FOLATES CONVERTED TO 5-METHYLTETRAHYDROFOLIC ACID (5-METHYL-THF)
INJECTION ORAL INTRAVENOUS
VD 16.2 LITER (65 KILOGRAM)
PPB 91 PERCENT
Cl 22.6 LITER / HOUR (65 KILOGRAM)
HT 1.3 HOUR
SOLUBILITY SOLUBLE IN WATER
PDB3UWL (CRYSTAL STRUCTURE OF ENTEROCCOCUS FAECALIS THYMIDYLATE SYNTHASE (EFTS) IN COMPLEX WITH 5-FORMYL TETRAHYDROFOLATE)